Reparations and Other Scams: Israeli Survivors Live in Poverty and Are Starving?
By Philip Giraldi | American Herald Tribune | July 5, 2020
The issue of reparations and other compensation has been much in the news of late, most particularly in relationship to possible payments to descendants of slaves in the United States to compensate them for their disadvantages brought about by what is claimed to be a persisting racist culture in the country. There is, of course, considerable resistance on the part of millions of non-black citizens who will have to foot the enormous bill even though they were not involved in slavery in any way, having arrived in the U.S. long after 1865, when involuntary servitude was abolished by the Thirteenth Amendment to the Constitution.
Reparations have been around for a long time, normally being exacted by the winners in a war against the losers, who automatically are blamed as the aggressors and therefore liable for the damages. Often the compensation comes in the form of territory, witness for example the German acquisition of Alsace-Lorraine from the French after the Franco-Prussian war followed by its return to France after the First World War. The Germans also were made to endure considerable cash and in-kind payments, primarily to France, after losing the First World War. The terms of the Treaty of Versailles were so onerous that they were subsequently blamed for perpetuating Franco-German hostility, leading inevitably to the Second World War.
Israel and Jewish groups were major beneficiaries of the reparations and restitution programs that were created as a result of World War Two. The Luxembourg Agreement signed in 1952 committed West Germany to pay Israel a sum of 3 billion Deutsche Marks over the next fourteen years, which was at the time an enormous sum. An additional 450 million marks were paid to the World Jewish Congress. The payments that were made to the State of Israel regarded the government as the de facto heir to war victims who had no surviving family or who could not otherwise be identified. The money was mostly invested in the Israeli infrastructure and was significant in aiding in the initial development of the economy of the new state, but there were also considerable barter arrangements whereby Israel purchasing agents obtained German manufactured goods and raw materials.
The reparations program was modified at various points to expand those eligible for benefits and continued to operate long after the fourteen-year term initially envisioned had expired. As of 2012, when the program was 60 years old, it was still fully operational and Germany had paid the Jewish state an estimated $89 billion.
In the 1990s, Israel and Jewish groups began to go after other property that they claimed had either been sold at below market prices as Jews began to flee Germany or otherwise lost. Money trails in Swiss banks were investigated to chart the movement of funds that had originally been derived from Jewish owned property. Individual companies, mostly in Germany, were pressured by survivor groups to provide reparations to former forced laborers, leading the Berlin government in 1999 to establish a separate fund to assist survivors of the so-called holocaust. The Swiss and Hungarians set up similar funds and The World Jewish Restitution Organization was established to organize these efforts. In America, the U.S. Foreign Claims Settlement Commission pressured Germany in 1998-9 to compensate Jewish survivors who had arrived in the United States after the war.
Israel, of course, has a vested interest in continuing the flow of Euros by making Germans and other Europeans continue to feel guilty over the war. In 2007 the Israelis pressured the German government to expand the pension program for Jewish survivors of 1939-1945 who had wound up in Israel. In 2009 Israel demanded compensation of between 450 million and 1 billion Euros ($1,120,000,000 currently) for 30,000 claimed former slave laborer-survivors. And the requirements for eligibility for a payment or pension continue to become more permissive. A Jewish survivor qualifies if he lived in “a ghetto” for 12 months as will anyone who can demonstrate that he “hid from” the Nazis for at least six months. One acceptable “ghetto” is in Shanghai China. And given the destruction of many public records, there has been considerable fraud. In 2010 auditors found evidence of a scheme to use fake identification documents to defraud the German government of more than $42 million.
And new and innovative sources of money are constantly being developed. The United States and Israel are currently pressuring Poland, which was occupied by the Germans, to compensate Jewish property owners. It is particularly difficult to do as much of Warsaw and nearly all its public records were destroyed in 1944. In August 2019, no less than 88 U.S. Senators signed a letter urging Secretary of State Mike Pompeo to “act boldly and with urgency” to compel Poland to resolve the property issue. The Poles have argued that the proceedings would be subject to massive fraud and “frivolous lawsuits” while the demands could bankrupt the country.
Meanwhile the French and Dutch rail systems, also under German control, have been forced to pay compensation to survivors because their trains were used to transport Jewish prisoners to camps.
The story of reparations and compensation is of particular interest, not only because the Second World War ended 75 years ago last month, but also because of attempts by Israel and Jewish groups to squeeze some final payments out of the remaining survivors. Quite astonishing is a “campaign” email currently being circulated by an organization calling itself LATET – Israeli Humanitarian Aid. It promotes itself as a charitable foundation with “All donations…tax-deductible in Israel, the U.S., Canada, Australia, France and the U.K.” It describes its activity as:
“Due to Covid-19, many impoverished Holocaust survivors experience an extended stay in deficient and insecure homes. MORE THAN EVER, SUPPORT URGENT HOME REPAIRS THE SURVIVORS CAN’T AFFORD. 1 in 4 Holocaust survivors in Israel lives in poverty. As a result of the COVID-19 outbreak, our elders spend all their time at home, mostly alone, in run-down apartments and they have nobody to turn to. The need to eliminate all safety hazards and obstacles relating to mobility, safety and comfort has grown and dozens of survivors are waiting for urgent assistance. Latet is the only organization in Israel providing Holocaust survivors in need with a complete aid package, including monthly food boxes, social support and an Emergency Fund for crucial needs. Since 2013, Latet has carried out more than 1,200 home repairs to increase the survivors’ quality of life, at no cost to them. Everyday, 40 Holocaust survivors die. Let’s make sure they spend their last days in decent conditions.
“Donate now. Latet was founded in 1996 and is the largest Israeli NGO combating poverty. Acting as an umbrella organization, Latet provides for the basic needs of populations living in poverty and food insecurity, giving ongoing food assistance to over 200,000 people in Israel. The organization operates the leading national food bank and runs impactful aid programs. For the last 10 years it has been the only organization in Israel providing a comprehensive aid package to Holocaust survivors in need, including a monthly food box, emergency fund for medical and paramedical needs, home restorations as well as ongoing social support in the form of personal volunteers and social events throughout the year. For more information about Latet: www.latet.org.il/en/”
One should not necessarily doubt the fundamental decency of LATET and what they are seeking to do, but their solicitation raises some serious questions about the Israeli government and Jewish charities that have been the recipients of more than $100 billion obtained as “reparations” from various foreigners, mostly Germans, specifically to address the needs of the so-called “Holocaust survivors.” How can the survivors be living in terrible conditions and even starving in a socialist country with a formidable safety net, one might ask Prime Minister Benjamin Netanyahu, when they have been granted pensions and other compensation since 1952?
The answer would appear to be pretty simple, that the money has gone directly to the Israeli government and to major Jewish private organizations which have engaged in the extortion racket and have proceeded to divert the flow from the “cash cow” for their own purposes. Soon there will be few survivors of the war left and the scam will presumably end, or maybe not, as there have been claims that the terror of the German camps can be passed on genetically and is inheritable?
Unfortunately, compensating for claims of Jewish suffering is a big business. The regular annual scandalous multi-billion dollar cash flow out of the United States Treasury to fill the Israeli coffers will continue seemingly forever. American taxpayers might be delighted to learn that during the past week Congress, beset by plague, civil unrest and a crumbling infrastructure, found time to move to approve an additional $500 million to Israel for its “defense.”
WHO’s Conflict of Interest?

US Secretary of State Michael Pompeo and WHO Director General Dr. Tedros Ghebreyesus, in Bern, Switzerland, on June 3, 2019. (State Dept. Photo by Ron Przysucha/ Public Domain)
By David Macilwain | American Herald Tribune | June 30, 2020
Last week the French National Assembly convened an inquiry into the “genealogy and chronology” of the Coronavirus crisis to examine the evident failures in its handling and will interview government ministers, experts and health advisors over the next six months. While we in the English-speaking world may have heard endless arguments over the failures of the UK or US governments to properly prepare for and cope with the health-care emergency, the crisis and problems in the French health system and bureaucracy have been similar and equally serious. Given the global cooperation and collaboration of health authorities and industry, the inquiry has global significance.
Judging by the attention paid by French media to the inquiry, which comes just as France is loosening the lock-downs and restarting normal government activities, it is set to be controversial and upsetting, exposing both incompetence and corruption.
Leading the criticism of the Macron government’s handling of the crisis are the most serious accusations that its prohibition of an effective drug treatment has cost many lives, a criticism put directly to the inquiry by Professor Didier Raoult, the most vocal proponent of the drug – Hydroxychloroquine. At his institute in Marseilles, early treatment with the drug of people infected with Sars-CoV-2 has been conclusively demonstrated to reduce hospitalization rates and shorten recovery times when given along with the antibiotic Azithromycin, and consequently to cut death rates by at least half.
Raoult has pointed to the low death rate in the Marseilles region of 140 per million inhabitants compared with that in Paris of 759 per million as at least partly due to the very different treatment of the epidemic in Marseilles under his instruction. The policies pursued by local health services there included early widespread testing for the virus and isolation and quarantining of cases, aimed both at protecting those in aged care and in keeping people from needing hospitalization with the help of drug treatments.
It incidentally seems quite bizarre that some countries – notably the US, UK and Australia, are only now embarking on large testing programs – and claiming a “second wave” in cases – which Raoult calls a “fantasme journalistique”. The consequent reimposition of severe lock-downs in some suburbs of Melbourne, and in Leicester in the UK is a very worrying development.
The efficacy of HCQ and Azithromycin is well illustrated – one should say proven – by this most recent review of its use on 3120 out of a total of 3700 patients treated at the Marseilles hospitals during March, April and the first half of May. Unlike the fraudulent study published and then retracted by the Lancet in May, the analysis in this review is exemplary, along with the battery of tests performed on patients to determine the exact nature of their infection and estimate the effectiveness of the drug treatment. The overall final mortality rate of 1.1% obscures the huge discrepancy in numbers between treated and untreated patients. Hospitalization, ICU, and death rates averaged five times greater in those receiving the “other” treatment – being normal care without HCQ-AZM treatment – equivalent to a placebo.
The IHU Marseilles study and its discussion points deserve close scrutiny, because they cannot be dismissed as unsubstantiated or biased, or somehow political, just because Professor Raoult is a “controversial figure”. There is a controversy, and it was well expressed by Raoult in his three hour presentation to the inquiry. His criticisms of health advisors to government include conflicts of interest and policy driven by politics rather than science. Raoult has been vindicated in his success, and can now say to those health authorities “if you had accepted my advice and approved this drug treatment, thousands of lives would have been saved.”
This is quite unlike similar statements in the UK and elsewhere, where claims an earlier imposition of lock-down would have cut the death toll in half are entirely hypothetical. As Prof. Raoult has also observed, the progress of this epidemic of a new and unknown virus was quite speculative, and its handling by authorities has failed to reflect that. In fact, one feels more and more that the “response” of governments all around the world has followed a strangely similar and inappropriately rigid scheme, of which certain aspects were de rigueur, particularly “social distancing”.
There seems little evidence that would justify this most damaging and extreme of measures to control an epidemic whose seriousness could be ameliorated by other measures – such as those advocated by Raoult’s Institute – which would have avoided the devastating “collateral damage” inflicted on the economy and society in the name of “staying safe”.
Prof. Raoult’s vocal and consistent criticism of the political manipulation of the Coronavirus crisis is hardly trivial however, to be finally excused as a “failure”- to impose lockdowns sooner, to have sufficient supplies of masks or ventilators, or to use more testing and effective contact tracing. What lies beneath appears to be, for want of a better word, a conspiracy.
As previously and famously noted by Pepe Escobar, French officials seemed to have foresight on the potential use of Hydroxychloroquine as a treatment for COVID-19 infection, with its cheapness and availability being a likely hindrance to pharmaceutical companies looking to make big profits from new drug treatments or vaccines. Of even greater significance perhaps, was the possibility – or danger – that the vast bulk of the population might become infected with the virus and recover quickly with the help of this cheap drug treatment, while bypassing the need, and possibly interminable wait for a vaccine.
Now it can be seen that in Western countries the demand for a vaccine is acute, and the market cut-throat, despite assurances from many quarters that “vaccines must be available to all” and that “manufacturers won’t seek to profit” from their winning product. (the profit will naturally be included in what their governments choose to pay them) The clear conflicts of interest between health officials, public and private interests make such brave pronouncements particularly hollow. Just one case is sufficient to illustrate this, as despite its unconvincing performance in combatting the novel Coronavirus, the drug developed and promoted by Dr Anthony Fauci and company Gilead, Remdesevir, was rapidly approved for use following a research trial sponsored by the White House.
More concerning however is what appears to be a conflict of interest in the WHO itself, possibly related to the WHO’s largest source of funding in the Gates organization. While the WHO has not actively opposed the use of Hydroxychloroquine against the virus infection for most of the pandemic, neither has it voiced any support for its use, such as might be suggested by its obvious benefits, and particularly in countries with poor health facilities and resources.
Had the WHO taken at least a mildly supportive role, acknowledging that the drug was already in widespread use and there was little to lose from trying it against COVID-19, then it is hard to imagine that those behind the recent fabricated Lancet paper would have pursued such a project. Without claiming that the WHO had some hand in the alleged study that set out to debunk HCQ treatment, it should be noted that the WHO was very quick to jump on the non-peer-reviewed “results” and to declare a world-wide cancellation of its research projects on the drug. And while it had to rescind this direction shortly afterward when the fraud was exposed, the dog now has a bad name – as apparently intended.
This stands in sharp contrast to the WHO’s sudden enthusiasm for the steroidal drug Dexamethasone, recently discovered by a UK research team to have had a mildly positive benefit on seriously ill COVID19 patients:
“The World Health Organization (WHO) plans to update its guidelines on treating people stricken with coronavirus to reflect results of a clinical trial that showed a cheap, common steroid could help save critically ill patients.
The benefit was only seen in patients seriously ill with COVID-19 and was not observed in patients with milder disease, the WHO said in a statement late Tuesday.
British researchers estimated 5,000 lives could have been saved had the drug been used to treat patients in the United Kingdom at the start of the pandemic.
“This is great news and I congratulate the government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough,” said WHO Director-General Tedros Adhanom Ghebreyesus in the press release.”
There is something more than ironic in the WHO’s interest in a different cheap and available drug that has also been widely used for decades, but which is no use in protecting those people in the target market for the vaccine. To me, and surely to Professor Raoult and his colleagues, this looks more like protecting ones business interests and investor profits, at the expense of public health and lives.
Postscript:
It has just been announced that GILEAD will start charging for its drug Remdesevir from next week at $US 2340 for a five-day course, or $US 4860 for private patients. Generic equivalents manufactured in poorer countries will sell for $US 934 per treatment course. Announcing the prices, chief executive Dan O’Day noted that the drug was priced “to ensure wide access rather than based solely on the value to patients”.
It seems hardly worth pointing out that six days treatment with Hydroxychloroquine costs around $US 7, so for the same cost as treating one patient with Remdesevir, roughly four hundred could be given Hydroxychloroquine. If this is compounded by the effective cure rate, Remdesevir treatment costs closer to one thousand times that of HCQ. The addition of Azithromycin and Zinc doubles the cost of HCQ treatment, but also increases its efficacy considerably.
Сriminal roots of Kosovo further exposed by Thaçi’s indictment in The Hague

By Paul Antonopoulos | June 29, 2020
Serbian President Aleksandar Vučić was due to meet Kosovo leader Hashim Thaçi on Saturday at the White House. This was at the behest of US envoy for Kosovo-Serbia negotiations, Richard Grenell, after his much-publicized success in organizing the meeting. However, his success was short lived after Thaçi became indicted for war crimes and crimes against humanity on June 24 by the Kosovo Specialist Chambers and Specialist Prosecutor’s Office.
The US meeting has been put on hold until further notice, but as Vučić revealed, the EU will take over discussions between Belgrade and Pristina at a later date. It appears that France and Germany specifically will spearhead these meeting with the French Embassy in Kosovo saying on Thursday that “France and Germany expect Dialogue between Kosovo and Serbia to resume soon. Together with Chancellor Merkel, President Macron remains ready to host a Summit in Paris.” German Ambassador to Kosovo Christian Heldt tweeted: “Our governments stand ready to be helpful with [a] proposed meeting in July.”
Due to prosecutors in The Hague indicting Thaçi’s alleged war crimes during the 1998-99 Kosovo war, Kosovo’s new prime minister, Avdullah Hoti, said he could not travel to Washington to conduct talks with Serbia.
“Thank you, Prime Minister Hoti. We understand your decision and we look forward to rescheduling the meeting soon,” Grenell wrote on Twitter.
US President Donald Trump was hoping for a foreign policy victory just before the upcoming elections, but rather, the Kosovo experiment created by Bill Clinton in the 1990’s is beginning to crack. Thaçi in 1993 became a prominent member of the “Kosovo Liberation Army” (KLA) and became responsible for the finances and armaments of the terrorist organization. The KLA financed its activities by turning Kosovo into a drug smuggling hub to distribute heroin and cocaine throughout Europe.
A 2008 report by German intelligence service BND accuses Thaçi of having deep involvement in organized crime, saying that “The key players (including Thaçi) are intimately involved in inter-linkages between politics, business, and organised crime structures in Kosovo,” and that Thaçi is leading a “criminal network operating throughout Kosovo.”
The charges laid against him by the prosecutor’s office in The Hague include murder, enforced disappearance of persons, persecution, and torture. He has also been accused of organ harvesting and drug trafficking by other reports and institutions. Although he has not been found guilty, it is well established that the KLA engaged in such activities, putting a mockery to the Albanian and Serbian Caucuses of US Congress suggestion in 2014 that Thaçi be nominated for the Nobel Peace Prize, the Geneva School of Diplomacy giving him a Doctor Honoris Causa degree as a Doctor of International Relations, and the Montenegrin town of Ulcinj giving him the title of Honorary Citizen of Ulcinj.
Before the scheduled meeting, Vučić said that Russian Foreign Minister Sergey Lavrov informed him about worrying information concerning various Western plans and ideas regarding the solution to the Kosovo crisis. Vučić pointed out that he exchanged opinions with Lavrov on a number of issues but that the key topic was the relationship between the two countries and Russia’s support for the integrity of Serbia and the situation in Kosovo.
“We received certain assessments from the Russian Federation […] which worried me. They concern various plans and ideas regarding the solution to the Kosovo crisis. I do not want to deceive anyone and hide from the public: obviously we are facing a difficult period, in which we will face great pressure to realize some plans that we did not officially or unofficially get, but based on the assessments of our Russian friends, it seems that we will have to be very careful in following every idea that is presented to us,” Vučić said at the press conference after their meeting.
Thanking Russia for supporting Serbia in the United Nations and in all international forums, Vučić said that it had been agreed that Serbia would consult with Russia on an almost daily basis, emphasizing that one thing was clear: “If at any time and in any place a solution is reached, any solution requires the consent of Russia. We do not want everyone else to be consulted without anyone asking Russia anything.”
He added that Russia supported the dialogue under the auspices of the EU, while Serbia is ready to listen to all other political actors and their ideas. He emphasized that Serbia will be able to protect its vital national interests, regardless of the price it will have to pay.
It begs the question whether the Trump administration now has the willingness to come up with a solution for Kosovo, especially as it is evident that the Albanians are connected with the Democrats in the U.S. and the criminal roots of Kosovo’s independence are being further exposed. The indictment against Thaçi is a major embarrassment for Washington as they have been the main backers of the illegal separation of Kosovo from Serbia. If Thaçi’s allegations are proven true by The Hague, it would mean Washington would have always known about the criminal activities of the KLA and the ongoing criminality in Kosovo’s government, but chose to ignore them to carve out a pro-US state from a pro-Russia Serbia.
Paul Antonopoulos is an independent geopolitical analyst.
Mysterious Individual ‘Blocking Release of Docs That May Expose Epstein’s Rich & Powerful Friends’
Sputnik – 24.06.2020
Jeffrey Epstein’s alleged sex slave Virginia Roberts, now Giuffre, was previously embroiled in a prolonged legal battle with the financier’s close associate Ghislaine Maxwell that ended in 2017. However, a cache of documents in the case listing the names of the financier’s closest associates remains sealed.
An anonymous person dubbed “John Doe” is trying to prevent the release of documents related to the Roberts Giuffre-Maxwell defamation case, requested by attorney and former Harvard professor Alan Dershowitz, the Daily Mail reported.
The protective order over the documents in the case was signed by now deceased New York Judge Robert Sweet, preventing the public release of the names of people closely associated with Jeffrey Epstein and potentially involved in his sex trafficking scandal.
Dershowitz, who was a friend of the convicted sexual offender, is now fighting a separate defamation case against Epstein’s alleged victim Virginia Giuffre launched in November 2019. He is calling for the protective order to be removed, arguing that the documents contain materials that could be crucial for his own defamation lawsuit.
On Tuesday, a number of attorneys involved in the case held a teleconference to debate whether the protective order can be loosened upon Dershowitz’s request. According to the Daily Mail, legal teams representing Giuffre, Maxwell, and a mysterious “John Doe” have strongly opposed the move.
The person’s attorneys, Nicholas Lewin and Paul Krieger, said in a letter to the court, that the protocol over the release of Giuffre-Maxwell case materials, which are expected to be unveiled on a “rolling basis”, should not be derailed.
“This marks Dershowitz’s second – or, by some measures, third – attempt to make an end-run around this Court’s carefully constructed unsealing protocol. Just as the Court denied Dershowitz’s prior attempts, it should deny this one”, the attorneys argued, a position that was shared by Maxwell’s and Giuffre’s legal teams.
The defamation lawsuit against Epstein’s alleged “madame” Ghislaine Maxwell was brought by Giuffre in September 2015 and eventually settled under seal two years later.
The media is now speculating that the anonymous individual involved in the case could be a public figure who is not willing to be associated with the Epstein scandal. The disgraced financier died in his prison cell in August 2019, while awaiting trial on sex-trafficking charges following accusations by several women, including Virginia Roberts Giuffre. Throughout his business career, Epstein was associated with a number of powerful figures, including Hillary and Bill Clinton, Prince Andrew, Donald Trump, and many others. Roberts Giuffre claims that she was sex-trafficked to some of them, including British Prince Andrew and Alan Dershowitz, accusations both men have strongly denied.
Ukrainian MP reveals new ‘Biden-Poroshenko’ tapes, claims VP’s son was paid ‘protection money’ by Burisma
RT | June 23, 2020
More tapes of what appear to be Joe Biden’s phone calls with the former president of Ukraine have surfaced, along with documents showing how much his son Hunter was paid by Burisma, a gas company desperate to avoid prosecution.
Ledgers show payments of $3.4 million from Burisma to Rosemont Seneca Bohai, the company co-founded by Hunter Biden, for “consulting services,” former prosecutor Konstantin Kulyk and Ukrainian MP Andrii Derkach revealed on Monday in Kiev.
Kulyk added that these services clearly amounted to “political protection of Burisma” and its owner Mykola Zlochevsky by US vice president at the time, Joe Biden.
Kulyk also told reporters that his office had evidence of Burisma’s lawyers offering $50 million to the government to make the case against the company and its founder go away – and not $6 million as was reported earlier.
The reason Burisma’s activities stood out from the white noise of general corruption in Ukraine following the US-backed coup in 2014 is that Zlochevsky sought to shield himself from scrutiny by hiring Hunter Biden as a board member, for a reported salary of $50,000 a month. Biden had no qualifications for the job, other than father being the top US official in charge of Ukraine.
Last month, Derkach released a batch of audio recordings of what sounded like Biden and then-President Petro Poroshenko of Ukraine, discussing everything from sacking a prosecutor looking into Burisma to what Kiev needed to do to qualify for an IMF bailout loan. He revealed more tapes on Monday.
The new recordings show ‘Biden’ micro-managing Ukraine’s internal affairs, asking ‘Poroshenko’ for a “favor,” discussing personnel appointments in the prosecutor-general’s office, assuring Poroshenko the FBI is not looking into claims of a Ukrainian MP who blew the whistle on massive corruption and vote-buying schemes, and so on.
The recordings have not been authenticated and Derkach himself was careful to say the voices “sound like” Poroshenko and Biden. He has turned the materials over to the prosecutor-general’s office, which is reportedly looking into charges of treason and abuse of power against the former president.
Poroshenko’s corruption and Hunter Biden’s job have had a major impact on US politics. Last year, Democrats accused President Donald Trump of soliciting foreign interference in the 2020 election by bringing up Burisma on a phone call with his Ukrainian counterpart Volodymyr Zelensky and threatening to withhold US military aid to Kiev. The House of Representatives actually impeached Trump on those charges, though he was acquitted in the Senate.
One of the witnesses in the process was Deputy Assistant Secretary of State for European and Eurasian Affairs George Kent. On Monday, Derkach named Kent as the liaison between Biden and Poroshenko, used to keep them informed of any developments regarding Burisma.
Poroshenko responded to the revelations by claiming they were a “fabrication” by Russia as “part of a large-scale hybrid war” intended to “undermine the Ukrainian-American strategic partnership that underlies the international coalition in support for Ukraine.”
He said the same exact thing about last month’s revelations, though on that occasion he also accused someone from Zelensky’s office of handing over “raw materials” to investigative journalists who then gave the recordings to Derkach.
“Deadly” Hydroxychloroquine (HCQ) to treat Covid 19: How the World’s Top Medical Journals, The Lancet and NEJM, Were Cynically Exploited by Big Pharma
By Elizabeth Woodworth | Global Research | June 14, 2020
Abstract and Background
A publishing scandal recently erupted around the use of the anti-malarial drug hydroxychloroquine (HCQ) to treat Covid 19. It is also known as quinine and chloroquine, and is on the WHO list of essential medicines.[i]
The bark of the South American quina-quina tree has been used to treat malaria for 400 years.[ii] Quinine, a generic drug costing pennies a dose, is available for purchase online. In rare cases it can cause dizziness and irregular heartbeat.[iii]
In late May, 2020, The Lancet published a four-author study claiming that HCQ used in hospitals to treat Covid-19 had been shown conclusively to be a hazard for heart death. The data allegedly covered 96,000 patients in 671 hospitals on six continents.[iv]
After the article had spent 13 days in the headlines, dogged by scientific objections, three of the authors retracted it on June 5.[v]
Meanwhile, during an expert closed-door meeting leaked May 24 in France, The Lancet and NEJM editors explained how financially powerful pharmaceutical players were “criminally” corrupting medical science to advance their interests.
*
On May 22, 2020, the time-honoured Lancet [vi]– one of the world’s two top medical journals – published the stunning claim that 671 hospitals on six continents were reporting life-threatening heart rhythms in patients taking hydroxychloroquine (HCQ) for Covid-19.
The headlines that followed were breath-taking.
Although wider access to the drug had recently been urged in a petition signed by nearly 500,000 French doctors and citizens,[vii] WHO and other agencies responded to the article by immediately suspending the clinical trials that may have cleared it for use.
North American headlines did not mention that HCQ has been on the WHO list of essential drugs since the list began in 1977. Nor did they mention an investigative report on the bad press that hydroxychloroquine had been getting prior to May 22, and how financial interests had been intersecting with medicine to favour Gilead’s new, more expensive drug, Remdesivir.[viii]
The statistics behind the headlines
As a Canadian health sciences librarian who delivered statistics to a large public health agency for 25 years, I sensed almost immediately that the article had to be flawed.
Why? Because health statistics are developed for different purposes and in different contexts, causing them to exist in isolated data “stovepipes.”[ix] Many health databases, even within a single region or country, are not standardized and are thus virtually useless for comparative research.
How, I wondered, could 671 hospitals worldwide, including Asia and Africa, report comparable treatment outcomes for 96,000 Covid patients? And so quickly?
The Lancet is strong in public health and surely suspected this. Its award-winning editor-in-chief, Dr. Richard Horton, has been in his job since 1995.[x]
So how could the damning HCQ claims have been accepted? Here is what I discovered.
The honour system in medical publishing
To some extent, authors submitting articles to medical journals are on the honour system, in which cited databases are trusted by the editors, yet are available for inspection if questioned.[xi]
On May 28, an open letter from 200 scientists to the authors and The Lancet requested details of the data and an independent audit. The letter was “signed by clinicians, medical researchers, statisticians, and ethicists from across the world.”[xii]
The authors declined to supply the data, or even the hospital names. Meanwhile, investigative analysis was showing the statistics to be deeply flawed.[xiii][xiv]
If this were not enough, the lead author was found to be in a conflict of interest with HCQ’s rival drug, Remdesivir:
“Dr. Mandeep Mehra, the lead co-author is a director at Brigham & Women’s Hospital, which is credited with funding the study. Dr. Mehra and The Lancet failed to disclose that Brigham Hospital has a partnership with Gilead and is currently conducting two trials testing Remdesivir, the prime competitor of hydroxychloroquine for the treatment of COVID-19, the focus of the study.”[xv]
In view of the foregoing, the article was retracted by three of its authors on June 5.
How did this fraud get past The Lancet reviewers in the first place?
The answer emerges from what has remained an obscure French interview, although it has been quoted in the alternative media.[xvi]
On May 24, a closed-door Chatham House expert meeting about Covid included the editors-in-chief of The Lancet and the NEJM. Comments regarding the article were leaked to the French press by a well-known health figure, Dr. Philippe Douste-Blazy,[xvii] who felt compelled to blow the whistle.
His resulting BFM TV interview was posted to YouTube with English subtitles on May 31,[xviii] but it was not picked up by the English-speaking media.
These were The Lancet editor Dr. Richard Horton’s words, as reported by Dr. Douste-Blazy:
“If this continues, we are not going to be able to publish any more clinical research data because pharmaceutical companies are so financially powerful today, and are able to use such methodologies as to have us accept papers which are apparently methodologically perfect, but which, in reality, manage to conclude what they want to conclude.” [xix]
Doust-Blazy made his own comments on Horton’s words:
“I never thought the boss of The Lancet could say that. And the boss of the New England Journal of Medicine too. He even said it was ‘criminal’. The word was used by them.”[xx]
The final words in Doust-Blazy’s interview were:
“When there is an outbreak like Covid, in reality, there are people like us – doctors – who see mortality and suffering. And there are people who see dollars. That’s it.”[xxi]
The scientific process of building a trustworthy knowledge base is one of the foundations of our civilization. Violating this process is a crime against both truth and humanity.
Evidently the North American media does not consider this extraordinary crime to be worth reporting.
Notes
[i] World Health Organization. “World Health Organization Model List of Essential Medicines, 21st ed.”, WHO, 2019, pp. 24, 25, 53 (https://www.who.int/medicines/publications/essentialmedicines/en/).
[ii] Jane Achan, et al., “Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria,” Malaria Journal, 24 May 2011 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121651/).
[iii] WebMD, “Quinine Sulfate” (https://www.webmd.com/drugs/2/drug-869/quinine-oral/details).
[iv] The Lancet, “RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, by Mandeep R. Mehra et al,” Lancet, 5 June 2010 (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext).
[v] Ibid.
[vi] Famous weekly British medical journal, founded in 1823.
[vii] Lee Mclaughlan, “Covid-19 France: petition for wider chloroquine access,” 6 April 2020 (https://www.connexionfrance.com/French-news/Time-wasted-over-use-of-choroquine-coronavirus-drug-says-petition-by-former-French-health-minister).
[viii] Sharyl Attkisson, “Hydroxychloroquine,” Full Measure, 18 May 2020 (https://www.youtube.com/watch?v=zB-_SV-y11Y). Attkisson is a five-time Emmy Award winner (https://en.wikipedia.org/wiki/Sharyl_Attkisson).
[ix] See “Stovepiping,” (https://en.wikipedia.org/wiki/Stovepiping) (accessed June 12, 2020).
[x] Dr. Horton’s career, professionalism, and awards are shown at https://en.wikipedia.org/wiki/Richard_Horton_(editor)(accessed June 12, 2020).
[xi] The Lancet and NEJM editors could not be expected to comb through data from 671 hospitals to verify their accuracy – especially when submitted by four doctors.
[xii] The full-text letter and signatories appear at https://zenodo.org/record/3862789#.XuQiNmYTGhM
[xiii] Melissa Davey, “Questions raised over hydroxychloroquine study which caused WHO to halt trials for Covid-19,” The Guardian, 28 May 2020 (https://www.theguardian.com/science/2020/may/28/questions-raised-over-hydroxychloroquine-study-which-caused-who-to-halt-trials-for-covid-19).
[xiv] Melissa Davey et al, “Surgisphere: governments and WHO changed Covid-19 policy based on suspect data from tiny US company,” The Guardian, 3 June 2020 (https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine).
[xv] 1. Alliance for Human Research Protection, “The Lancet Published a Fraudulent Covid-19 Study,” 2 June 2020 (https://ahrp.org/the-lancet-published-a-fraudulent-study-editor-calls-it-department-of-error/).
- Brigham Health, “Two Remdesivir Clinical Trials Underway at Brigham and Women’s Hospital,” 30 March 2020 (https://www.brighamhealthonamission.org/2020/03/26/two-remdesivir-clinical-trials-underway-at-brigham-and-womens-hospital/).
[xvi] Vera Sharav, “Editors of The Lancetand the New England Journal of Medicine: Pharmaceutical Companies are so Financially Powerful They Pressure us to Accept Papers,” Health Impact News, 5 June 2020
[xvii] Dr. Philippe Douste-Blazy, MD, is a cardiologist, former French Health Minister; 2017 candidate for Director at WHO; and former Under-Secretary-General of the United Nations. See also: https://en.wikipedia.org/wiki/Philippe_Douste-Blazy.
[xviii] “(Eng Subs) Hydroxychloroquine Lancet Study: Former France Health Minister blows the whistle,” BFM TV, 31 May 2020 (https://www.youtube.com/watch?time_continue=2&v=ZYgiCALEdpE&feature=emb_logo).
[xix] Ibid.
[xx] Ibid.
[xxi] Ibid.
Copyright © Elizabeth Woodworth, Global Research, 2020
Media Blackout: The Federal Court Case To End Water Fluoridation!
Spiro Skouras | June 14, 2020
As we are inundated with headlines about violent riots and looting being passed off as mostly peaceful protests, or how the dreaded virus continues to spread in communities around the world. There is another story taking place which directly effects hundreds of millions of people globally that is being blacked out by the mainstream corporate media.
Unlike the aforementioned crisis’ which are being sited as the justification for the World Economic Forum’s Great Reset. This public health crisis actually has a rather simple solution. To end water fluoridation by no longer adding the toxic substance to the nations water supply.
You would think this would be a straightforward process considering the mountains of studies which conclude fluoride is a harmful neurotoxin attributed to lower IQ’s and ADHD. Unfortunately government regulatory agencies have been not only defending this practice for generations, they champion the forced medication as a great achievement in medical history.
Right now, in perhaps one of the most important trials of our time. The Fluoride Action Network is taking the Environmental Protection Agency (EPA) head on in an unprecedented court case that could lead to the end of water fluoridation in the US and possibly worldwide as other nations would likely follow suit.
In this interview, Spiro is joined by Dr. Paul Connett of the Fluoride Action Network to discuss the current court case against EPA and water fluoridation as the first week of the trial has come to an end and the second, possibly final week is about to begin.
Fluoride Action Network http://fluoridealert.org
Link & Times To Watch The Trial Live http://fluoridealert.org/issues/tsca-…
Spiro’s Interview with Dr. Paul Connett & his Son, Attorney Michael Connett https://www.youtube.com/watch?v=VQAjW…
Financial Conflicts & the Retracted COVID Research
Lead author, paid by drug companies, gives the all-clear to products those companies sell. World’s leading medical journal fails transparency test.
By Donna Laframboise | Big Picture News | June 22, 2020
Mandeep Mehra is a professor at Harvard Medical School, and the medical director of a Boston hospital department. That city being a coronavirus hotspot, life hasn’t been normal there for some time.
He’s also the lead author of two COVID-19 research papers that were retracted shortly after being published in prestigious medical journals. Lancet boss Richard Horton calls the one published in his journal a “monumental fraud.”
The other, which has received less attention, appeared in the New England Journal of Medicine (NEJM). Titled Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19, it runs to seven pages and was retracted because its authors now admit the data on which it relies cannot be validated.
During this pandemic, physicians have been desperate for information to help guide their decisions. Eric Rubin, editor-in-chief of the NEJM, recently explained to the New York Times,
I’m an infectious disease doctor, I treat Covid-19 patients. I’ve been in the hospital recently treating patients, and we have no idea what to do. I’m the primary driver at the journal of saying, ‘We have to get data out there that people can use.’ [bold added]
Many hypotheses have been advanced. Many questions remain unanswered. For example, there’s uncertainty about whether some widely prescribed medications might be complicating the picture. Are people who take high blood pressure pills – ACE inhibitors and ARBs (angiotensin receptor blockers) – at higher risk? Should they switch to alternatives until the pandemic is over (see here, here, and here)?
Similarly, should people on cholesterol-lowering statins follow advice published in the British Medical Journal and stop taking these drugs if they develop a serious case of COVID-19? Statins are, after all, prescribed for preventative purposes, to help avert heart problems longer term.
Mehra’s paper claimed to have examined patient records from three continents and to have found no evidence that any of these drugs increase the death rate of those who had heart issues prior to the coronavirus. Indeed, it declares that “the use of ACE inhibitors, and the use of statins were associated with a better chance of survival” in women.
But even if this data was 100% reliable, there would still be two enormous problems with this research:
#1: The lead author has financial ties to companies that sell those drugs.
#2: Neither the authors nor the journal informed us of this salient fact up front, in a transparent manner.
The paper reports, on page 1, that the research was “Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women’s Hospital.”
Mehra’s Harvard e-mail address also appears on page 1. Readers are told that’s where reprint requests should be addressed (reprints are frequently distributed to third party doctors by drug companies as marketing material, and can be a considerable source of revenue for medical journals).
At the very end of the paper, on page 7, in fine print, we’re reminded that the research was supported by the William Harvey Distinguished Chair. Only then are we advised that “Disclosure forms by the authors are available with the full text of this article at NEJM.org.”
One must go to the trouble of tracking down the online version of the paper, and downloading that separate 16-page PDF, to discover the lead author has a serious conflict of interest. There, on page 12, we read:
Dr. Mehra reports personal fees from Abbott, personal fees from Medtronic, personal fees from Janssen, personal fees from Mesoblast , personal fees from Baim Institute for Clinical Research, personal fees from Portola, personal fees from Bayer, personal fees from Triple Gene, personal fees from Leviticus, personal fees from NupulseCV, personal fees from FineHeart, other from Riovant, outside the submitted work;. [sic, bold added]
Abbott Laboratories sells statins and ACE inhibitors. The company is described as a “top key player,” a “major giant,” and a “leading player” in those global marketplaces.
Likewise, Bayer AG is a major global player in the ARB market.
So a lead author who has financial relationships with two companies that sell certain classes of drugs took the time, during a pandemic, to give those drugs an all-clear.
On it’s website, the New England Journal of Medicine calls itself “the world’s leading medical journal.” Why did it choose to bury this vital piece of information?
Retracted Papers Written by Journal VIP
By Donna Laframboise | Big Picture News | June 17, 2020
The lead author of two retracted COVID-19 papers is editor-in-chief of an Elsevier medical journal.
Earlier this month, two high-profile research papers were retracted on the same day. One, published in The Lancet, had concluded that coronavirus patients treated with malaria drugs were more likely to die. Published on May 22, it was officially withdrawn 13 days later.
Another, published in the New England Journal of Medicine, found no evidence that widely prescribed medications increase the death rate of hospitalized COVID-19 patients with pre-existing heart problems.
The lead author in both instances was Mandeep Mehra, a professor of medicine at Harvard Medical School, and the person in charge of the Heart and Vascular Center at Boston’s Brigham and Women’s Hospital.
The second listed author was Sapan Desai. An online bio describes him as an “internationally-recognized double board certified vascular surgeon.” Desai is the founder of Surgisphere Corporation, a data analytics firm which claimed to have acquired 96,000 highly-detailed electronic medical records of COVID-19 patients from 671 hospitals on six continents.
The Lancet paper’s dramatic findings interrupted drug trials and changed government policy in multiple countries. It also increased the anxiety of coronavirus patients who’d been participating in those trials.
But six days after the paper appeared, more than 100 “clinicians, medical researchers, statisticians, and ethicists” addressed an open letter to the authors, and to Lancet editor-in-chief Richard Horton, questioning the integrity of the cited data.
Why were the hospitals which supplied this data not identified? Why weren’t standard statistical practices employed? Why no ethics review? Why didn’t the paper invite other researchers to examine for themselves the underlying data and computer code?
According to these experts, the medication dose sizes discussed were odd, drug ratios sounded “implausible,” the Australian data was obviously erroneous, and the African data seemed “unlikely.”
Yet none of The Lancet‘s peer-reviewers apparently noticed. “In the interests of transparency,” said the signatories of the open letter, “we also ask The Lancet to make openly available the peer review comments that led to this manuscript to be accepted for publication [sic].”
An article in the New York Times says these events “have alarmed scientists worldwide who fear that the rush for research on the coronavirus has overwhelmed the peer review process.” Lancet editor Horton, it reports, now describes the retracted paper as a “fabrication” and “a monumental fraud.”
A headline in the UK Guardian says The Lancet has made one of the biggest retractions in modern history. How, asks the article that follows,
did a paper of such consequence get discarded like a used tissue by some of its authors only days after publication? If the authors don’t trust it now, how did it get published in the first place?…the sad truth is peer review in its entirety is struggling…
Neither of those articles mentioned an astonishing fact. Lead author Mehra is himself the editor-in-chief of The Journal of Heart and Lung Transplantation. Part of Elsevier’s scholarly publishing empire, this monthly journal hires editors for five-year terms. Mehra’s second term is coming to end, and last year the search for a replacement began.
As the posted job description explains, the editor-in-chief is responsible for overseeing the peer review of papers submitted to that journal. He or she is constantly evaluating research, sorting solid science from weak science. The new editor-in-chief, we’re told, must have “a demonstrated understanding of statistics and statistical methods.”
So how could a man who has spent the past 10 years in such a role have authored this pair of retracted papers? How could anyone with any statistical sophistication have taken such dodgy data at face value?
“No matter which way you examine the data, use of these [malaria] drug regimens did not help,” Mehra declared in a press release when The Lancet paper was published. But it now appears he didn’t directly examine the data at all. On the day the paper was retracted, he explained in a subsequent statement:
Dr. Desai, who served as a co-author and whose team maintained this observational database, conducted various analyses. As first author, these were provided to me, and on the basis of these analyses, we published two peer-reviewed papers…
In other words, this longtime editor-in-chief took someone else’s word for it. He failed to ask elementary questions. He took it on faith that the analyses had been properly conducted. Mehra continued:
It is now clear to me that in my hope to contribute this research during a time of great need, I did not do enough to ensure that the data source was appropriate for this use. For that, and for all the disruptions – both directly and indirectly – I am truly sorry.
This, ladies and gentlemen, is the vaunted peer review system in action. Naive trust. Blind faith. By Mehra. By The Lancet. By the New England Journal of Medicine. Even when real lives, right now, hang in the balance.
Four years ago, I authored a report demonstrating that peer review is merely a sniff test. Typically performed by unpaid volunteers, it’s based on wholly subjective criteria, and is highly influenced by the pre-existing beliefs of those doing the reviewing. My report contains this paragraph:
In 2014, Science announced measures to provide deeper scrutiny of statistical claims in the research it publishes. John Ioannidis, the author of a seminal 2005 paper asserting that most published research findings are false, called this announcement “long overdue”. In his opinion, statistical review has become more important than traditional peer review for a “majority of scientific papers”.
In many places, statistical review still doesn’t occur. Even in our current situation, when COVID-19 research has the power to halt drug trials and change history, the vetting process at medical journals is a joke.





